MENU
+Compare
BMY
Stock ticker: NYSE
AS OF
Feb 3 closing price
Price
$55.99
Change
+$11.31 (+25.31%)
Capitalization
113.98B

BMY Bristol-Myers Squibb Co Forecast, Technical & Fundamental Analysis

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders... Show more

BMY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for BMY with price predictions
Feb 02, 2026

BMY in downward trend: price expected to drop as it breaks its higher Bollinger Band on January 07, 2026

BMY broke above its upper Bollinger Band on January 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In of the 40 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for BMY moved out of overbought territory on January 15, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where BMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BMY turned negative on January 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 02, 2026. You may want to consider a long position or call options on BMY as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 195 cases where BMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.143) is normal, around the industry mean (9.533). P/E Ratio (18.852) is within average values for comparable stocks, (24.433). Projected Growth (PEG Ratio) (1.120) is also within normal values, averaging (1.907). BMY has a moderately high Dividend Yield (0.045) as compared to the industry average of (0.025). P/S Ratio (2.374) is also within normal values, averaging (3.990).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock worse than average.

View a ticker or compare two or three
BMY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

BMY is expected to report earnings to fall 6.13% to $1.53 per share on February 05

Bristol-Myers Squibb Co BMY Stock Earnings Reports
Q4'25
Est.
$1.53
Q3'25
Beat
by $0.11
Q2'25
Beat
by $0.40
Q1'25
Beat
by $0.28
Q4'24
Beat
by $0.20
The last earnings report on October 30 showed earnings per share of $1.63, beating the estimate of $1.52. With 11.08M shares outstanding, the current market capitalization sits at 113.98B.
A.I.Advisor
published Dividends

BMY paid dividends on February 02, 2026

Bristol-Myers Squibb Co BMY Stock Dividends
А dividend of $0.63 per share was paid with a record date of February 02, 2026, and an ex-dividend date of January 02, 2026. Read more...
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceuticals products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
Route 206 and Province Line Road
Phone
+1 609 252-4621
Employees
34100
Web
https://www.bms.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PHYS37.102.10
+6.00%
Sprott Physical Gold Trust
EWI56.930.56
+0.99%
iShares MSCI Italy ETF
GYLD13.690.06
+0.40%
Arrow Dow Jones Global Yield ETF
XMAR40.12-0.04
-0.10%
FT Vest U.S. Eq Enh & ModBufETF-Mar
TETH11.46-0.12
-1.04%
21Shares Ethereum ETF

BMY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been closely correlated with PFE. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if BMY jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
+1.53%
PFE - BMY
67%
Closely correlated
+0.83%
MRK - BMY
59%
Loosely correlated
+2.81%
AMGN - BMY
58%
Loosely correlated
+0.82%
ABBV - BMY
58%
Loosely correlated
+1.18%
BIIB - BMY
54%
Loosely correlated
-0.44%
More

Groups containing BMY

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
+1.53%
BMY
(2 stocks)
97%
Closely correlated
-1.58%